科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02171 科济药业-B

休市中 06-12 16:08:21

15.020

-0.930

-5.83%

最高16.500	最低15.020	成交量1,106万
今开15.980	昨收15.950	日振幅9.28%
总市值89.37亿	流通市值89.37亿	总股本5.95亿
成交额1.73亿	换手率1.86%	流通股本5.95亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02171","market":"HK","secType":"STK","nameCN":"科济药业-B","latestPrice":15.02,"timestamp":1781251701003,"preClose":15.95,"halted":0,"volume":11058000,"delay":0,"changeRate":-0.05830721003134795,"floatShares":595000000,"shares":595000000,"eps":-0.177264,"marketStatus":"休市中","change":-0.93,"latestTime":"06-12 16:08:21","open":15.98,"high":16.5,"low":15.02,"amount":172542311,"amplitude":0.09279,"askPrice":15.02,"askSize":3796000,"bidPrice":15,"bidSize":126000,"shortable":3,"etf":0,"ttmEps":-0.182,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781487000000},"marketStatusCode":7,"adr":0,"listingDate":1623945600000,"exchange":"SEHK","adjPreClose":15.95,"openAndCloseTimeList":[[1781227800000,1781236800000],[1781240400000,1781251200000]],"volumeRatio":1.834727,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02171/wiki","defaultTab":"wiki","newsList":[{"id":"1198289310","title":"科济药业-B更新2026年5月股份变动月报表，股本增至602,493,998股","url":"https://stock-news.laohu8.com/highlight/detail?id=1198289310","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198289310?lang=zh_cn&edition=full","pubTime":"2026-06-04 20:01","pubTimestamp":1780574517,"startTime":"0","endTime":"0","summary":"2026年6月4日，科濟藥業控股有限公司公告了2026年5月股份变动月报表，报告期为2026年5月1日至2026年5月31日。另于2025年5月22日，公司回购455,000股普通股，目前该等股份尚未注销。2026年5月26日，公司以每股19.84港元的价格配售并发行23,700,000股新股，叠加期权行使及股权激励的影响后，本月实际新增发行股份23,733,250股。截至2026年5月31日，公司已发行股份总数达594,675,998股，加上库藏股份后，共有602,493,998股。该月报由公司的执行董事李宗海于2026年6月4日签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162683138","title":"异动解读｜科济药业-B盘中下跌5.14%，折让配股稀释效应叠加板块走弱持续压制股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1162683138","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162683138?lang=zh_cn&edition=full","pubTime":"2026-06-02 11:33","pubTimestamp":1780371237,"startTime":"0","endTime":"0","summary":"6月2日，科济药业-B盘中下跌5.14%，报16.41港元/股，成交额3187.27万港元。折价配股带来的稀释效应叠加机构持续减持，短期对市场情绪形成压制。资金用途方面，70%将用于创新药全球临床开发，15%用于研发与生产设备设施，15%用于营运资金。此外，港股生物科技板块整体走弱，三生制药跌7.4%、科伦博泰生物跌3.95%、康方生物跌3.02%、百济神州跌2.22%、信达生物跌2.1%，行业估值承压进一步加剧个股调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126274477","title":"异动解读｜科济药业-B盘中下跌5.02%，折让配股稀释效应叠加机构减持持续压制股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1126274477","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126274477?lang=zh_cn&edition=full","pubTime":"2026-06-01 11:08","pubTimestamp":1780283287,"startTime":"0","endTime":"0","summary":"6月1日，科济药业-B盘中下跌5.02%，报17.23港元/股，成交额5237.98万港元。折价配股带来的稀释效应叠加机构持续减持，短期对市场情绪形成压制。资金用途方面，70%将用于创新药全球临床开发，15%用于研发与生产设备设施，15%用于营运资金。此外，港股生物科技板块整体表现分化，信达生物跌2.64%、百济神州跌2.32%、科伦博泰生物跌3.25%，行业估值承压进一步加剧个股调整。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640642981","title":"科济药业-B(02171)：舒瑞基奥仑赛注射液研究成果于2026年ASCO年会上进行壁报展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2640642981","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640642981?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:25","pubTimestamp":1780273534,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科济药业-B 发布公告，舒瑞基奥仑赛注射液在晚期胃癌╱胃食管交界处腺癌患者中作为一线治疗后的序贯治疗的长期分析研究结果于美国中部夏令时间2026年5月30日13:30 – 16:30在2026年美国临床肿瘤学会年会上进行壁报展示。发表在2026ASCO年会上的摘要标题为“舒瑞基奥仑赛注射液作为晚期胃癌一线治疗后序贯治疗的长期随访 —— 一项亚组分析”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448248.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1585","BK1161","BK1587","02171","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129638005","title":"科济药业-B公布Satri-Cel用于胃癌一线治疗后序贯疗法的长期随访结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1129638005","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129638005?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:16","pubTimestamp":1780273010,"startTime":"0","endTime":"0","summary":"在2026年美国临床肿瘤学会（ASCO）年会上，科济药业-B（CARSGEN-B）公布了其CAR-T细胞疗法Satri-Cel作为胃癌一线治疗后序贯疗法的长期随访研究数据。\n这些长期随访结果进一步评估了Satri-Cel在该治疗模式下的疗效与安全性表现。数据显示，该疗法在特定患者群体中展现出持久的临床获益潜力，为晚期胃癌患者提供了新的治疗选择方向。\n此次数据发布是科济药业-B在实体瘤CAR-T疗法领域持续研发进展的体现。公司致力于探索创新细胞疗法在包括胃癌在内的多种癌症治疗中的应用前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171","BK1574","BK1585","BK1161","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169369085","title":"异动解读｜科济药业-B盘中下跌5.19%，折让配股稀释效应持续压制股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1169369085","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169369085?lang=zh_cn&edition=full","pubTime":"2026-05-28 10:45","pubTimestamp":1779936333,"startTime":"0","endTime":"0","summary":"5月28日，科济药业-B盘中下跌5.19%，报17.18港元/股，成交额2793.5万港元。配售完成后公司已发行股本增至约5.95亿股。折价配股带来的稀释效应叠加股东持仓调整，短期持续对市场情绪形成压制。此外，港股生物科技板块整体走弱，信达生物跌2.09%、康方生物跌2.0%、百济神州跌2.05%、三生制药跌4.82%，行业估值承压进一步加剧个股调整。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184440131","title":"科济药业-B完成逾2373万股新股发行并披露回购股份未注销","url":"https://stock-news.laohu8.com/highlight/detail?id=1184440131","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184440131?lang=zh_cn&edition=full","pubTime":"2026-05-26 23:07","pubTimestamp":1779808043,"startTime":"0","endTime":"0","summary":"科济药业-B于2026年5月26日发布公告，披露在一般授权下完成新股认购及多次股权激励行使，共涉及约23,733,250股普通股。认购部分的23,700,000股发行价格为每股19.84港元，占发行前已发行股本约4.15%。上述发行完成后，科济药业-B已发行股本增至594,675,998股，另有库藏股7,818,000股，合计602,493,998股。截至本公告日，该等回购股份尚未注销。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"科济药业-B完成逾2373万股新股发行并披露回购股份未注销","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638545858","title":"科济药业-B(02171)完成先旧后新配售2370万股 净筹约4.62亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2638545858","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638545858?lang=zh_cn&edition=full","pubTime":"2026-05-26 22:56","pubTimestamp":1779807402,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科济药业-B(02171)发布公告，配售事项已于2026年5月19日根据配售协议的条款及条件完成，合共2370万股配售股份已由联席配售代理基于最大努力以每股配售股份19.84港元的配售价，成功配售予不少于六名承配人。据董事作出一切合理查询后所深知、尽悉及确信，各承配人及其最终实益拥有人均为独立第三方，且并非与卖方一致行动。认购事项的所得款项总额及估计所得款项净额(经扣除配售事项及认购事项所产生的所有费用、成本及开支)分别约为4.70亿港元及4.62亿港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446295.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1585","BK1587","02171","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112542519","title":"异动解读｜科济药业-B盘中下跌5.2%，折让配股及创新药板块承压拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1112542519","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112542519?lang=zh_cn&edition=full","pubTime":"2026-05-26 10:11","pubTimestamp":1779761510,"startTime":"0","endTime":"0","summary":"5月26日，科济药业-B盘中下跌5.2%，报17.57港元/股，成交额4754.91万港元。折价配股带来的稀释效应叠加股东持仓调整，短期对市场情绪形成压制。此外，港股创新药板块近期整体走弱，行业估值承压亦加剧个股调整。科济药业控股有限公司主要从事开发CAR-T细胞疗法，覆盖血液恶性肿瘤、实体瘤及自身免疫性疾病领域，主要产品包括赛恺泽、舒瑞基奥仑赛注射液及通用型CAR-T细胞产品。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636893927","title":"科济药业-B(02171)股东将股票由UBS Securities Hong Kong转入花旗银行 转仓市值4.32亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2636893927","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636893927?lang=zh_cn&edition=full","pubTime":"2026-05-20 08:08","pubTimestamp":1779235706,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，5月19日，科济药业-B股东将股票由UBS Securities Hong Kong转入花旗银行，转仓市值4.32亿港元，占比4%。科济药业发布公告称，于5月15日与主要股东益杰生物技术(卖方)及联席配售代理订立协议，拟向不少于六名独立专业投资者以先旧后新方式配售2370万股，占扩大后股本约3.99%，每股作价19.84港元，较公司5月14日收市价21.92港元折让约9.49%，所得款项净额约为4.62亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0648001328.SGD","BK1587","02171","LU1244550494.USD","IE00BSNM7G36.USD","LU0477156953.USD","LU0203345920.USD","LU0130102774.USD","LU1244550221.USD","BK4559","LU1267930227.SGD","LU0072461881.USD","LU2125154935.USD","LU1162221912.USD","BK1585","LU0106831901.USD","LU0170899867.USD","BK4504","BK4566","LU0162691827.USD","LU2125154778.USD","LU0310800965.SGD","LU0052756011.USD","LU0130517989.USD","LU1506573853.SGD","BK1574","LU0980610538.SGD","BK4207","LU2417539215.USD","LU1366192091.USD","LU2456880835.USD","LU0098860793.USD","BK4585","BK1161","LU0314106906.USD","LU2360032135.SGD","LU1244550577.SGD","LU2236285917.USD","LU1201861249.SGD","LU1668664300.SGD","LU1791807156.HKD","LU0203347892.USD","LU2462157665.USD","BK4588","LU0320765646.SGD","BK4534","LU0128525689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636046305","title":"港股异动 | 创新药概念股全线下挫 全球债市抛售潮初现 高利率或冲击行业估值及融资端","url":"https://stock-news.laohu8.com/highlight/detail?id=2636046305","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636046305?lang=zh_cn&edition=full","pubTime":"2026-05-18 11:38","pubTimestamp":1779075485,"startTime":"0","endTime":"0","summary":"消息面上，霍尔木兹海峡持续封锁，正推动油价攀升至每桶105美元以上。全球债券市场抛售潮征兆已现。美国10年期国债收益率升至4.5%以上，日本30年期国债收益率首次突破4%，英国长期国债收益率则升至28年来的最高水平，引发市场对于未来全球金融环境趋紧的担忧。其中，4 月全球、美国、国内创新药投融资均呈现强劲复苏的态势。但也有分析人士指出，若全球利率环境进入更高水平且持续，将冲击创新药行业估值及融资端。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442779.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06978","BK1587","09939","02171","03141","159992","BK1585","09966","BK4588","02137","VXUS","BK1515","BK4585","BK1574","09141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635720615","title":"科济药业-B(02171)股东将股票存入UBS Securities Hong Kong 存仓市值19.27亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2635720615","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635720615?lang=zh_cn&edition=full","pubTime":"2026-05-15 08:15","pubTimestamp":1778804141,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，5月14日，科济药业-B(02171)股东将股票存入UBS Securities Hong Kong，存仓市值19.27亿港元，占比14.5%。科济药业-B发布公告，于2026年5月15日(交易时段前)，公司、卖方益杰生物技术控股有限公司及联席配售代理订立配售协议，据此，卖方同意出售，而联席配售代理同意担任卖方的代理，并基于最大努力促使不少于六名承配人以每股配售股份19.84港元的配售价购买不超过2370万股配售股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442004.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02171","BK1587","BK1574","BK1161","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635272710","title":"科济药业-B(02171)拟折让约9.49%先旧后新配股 净筹约4.62亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2635272710","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635272710?lang=zh_cn&edition=full","pubTime":"2026-05-15 08:10","pubTimestamp":1778803826,"startTime":"0","endTime":"0","summary":"配售价为每股配售股份19.84港元，较股份于最后交易日在联交所所报收市价每股21.92港元折让约9.49%。假设除配发及发行认购股份以及配售股份悉数获配售外，公司已发行股本于本公告日期至认购事项完成期间并无变动，2370万股将予配售的现有股份占：公司于本公告日期之现有已发行股本约4.15%;及公司于紧随认购事项完成后经配发及发行认购股份扩大的已发行股本约3.99%。认购事项之所得款项总额及估计所得款项净额预计分别约为4.7亿港元及4.62亿港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1585","BK1574","02171","BK1161","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635943788","title":"格隆汇个股放量排行榜 | 5月13日","url":"https://stock-news.laohu8.com/highlight/detail?id=2635943788","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635943788?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:30","pubTimestamp":1778664605,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日腾讯音乐-SW(01698)、阳光保险(06963)、上海电气(02727)、轻松健康(02661)、弘毅文化集团(00419)、FIT HON TENG(06088)、京城机电股份(00187)、北方矿业(00433)、心玮医疗-B(06609)、同源康医药-B(02410)、富通科技(00465)、京东物流(02618)、云顶新耀(01952)、赛晶科技(005","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/13173057083788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["81024","00169","01024","02172","02306","02126","01905","01548","03700","09992","06186","06996","02013","02256","01833","00136","06049","02171","09888","00013","09688","02158","03888","03692","00772","02276","01951","09626","00719","06963","06969","06609","09858","01783","02192","02252","06660","02197","02618","01060","01440","01952","06160","09699","06060","00909","02096","02285","01357","00762"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135873113","title":"异动解读 | CAR-T研究成果获国际认可，科济药业-B盘中大涨6.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=1135873113","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135873113?lang=zh_cn&edition=full","pubTime":"2026-05-13 09:43","pubTimestamp":1778636632,"startTime":"0","endTime":"0","summary":"科济药业-B今日盘中股价大幅上涨6.01%，引起了市场的高度关注。消息面上，公司近期接连披露了多项CAR-T细胞疗法的重要研究进展。此外，公司基于自主研发THANK-u Plus平台开发的两款通用型CAR-T细胞疗法——靶向BCMA的CT0596和靶向CD19/CD20的CT1190B的研究摘要，也已被欧洲血液学协会年会接受，并将进行壁报展示。这些研究成果获得国际顶级学术会议的认可，显著提升了市场对公司创新研发实力和未来商业化潜力的信心，被认为是推动股价上涨的主要动力。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115124148","title":"科济药业-B更新4月股份变动月报表，股本小幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1115124148","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115124148?lang=zh_cn&edition=full","pubTime":"2026-05-07 17:36","pubTimestamp":1778146566,"startTime":"0","endTime":"0","summary":"2026年5月7日，科济药业控股有限公司发布截至2026年4月30日的股份变动月报表。公告显示，公司注册股本维持在200,000,000,000股普通股，面值每股0.00000025美元，总注册股本为50,000美元，较上月无变化。在已发行股份及库存股份方面，截至4月30日，科济药业-B已发行股份由3月底的570,352,999股增至570,942,748股，库存股份数维持在7,818,000股，合计发行股本由578,170,999股增加至578,760,748股，单月净增589,749股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633191971","title":"科济药业-B盘初涨超3% CT0596与CT1190B研究结果摘要已被EHA年会接受进行壁报展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2633191971","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633191971?lang=zh_cn&edition=full","pubTime":"2026-05-06 09:47","pubTimestamp":1778032020,"startTime":"0","endTime":"0","summary":"　　科济药业-B盘初涨超3%，截至发稿，股价上涨1.90%，报21.50港元，成交额1947.27万港元。　　近日，科济药业-B发布公告，CT0596用于治疗复发╱难治性多发性骨髓瘤╱浆细胞白血病的IIT的研究结果摘要，及CT1190B用于治疗复发╱难治性B细胞非霍奇金淋巴瘤的IIT的研究结果摘要，已被2026年欧洲血液学协会年会接受进行壁报展示。　　CT0596是一款靶向BCMA的通用型CAR-T细胞疗法，基于科济药业自主研发的THANK-u Plus平台开发，目前正在R/R MM或PCL中开展IIT进行评估。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-05-06/doc-inhwxhnr3538418.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1587","BK1574","02171","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630393819","title":"科济药业-B(02171)：CT0596及CT1190B的研究结果摘要已被2026年EHA年会接受以壁报展示呈列","url":"https://stock-news.laohu8.com/highlight/detail?id=2630393819","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630393819?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:05","pubTimestamp":1777287942,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科济药业-B 发布公告，CT0596用于治疗复发╱难治性多发性骨髓瘤╱浆细胞白血病的IIT的研究结果摘要，及CT1190B用于治疗复发╱难治性B细胞非霍奇金淋巴瘤的IIT的研究结果摘要，已被2026年欧洲血液学协会年会接受进行壁报展示。摘要和进一步信息将于欧洲中部夏令时间2026年5月12日15:30后公布。CT0596显示出初步良好的安全性及令人鼓舞的疗效信号。本公司计划于2026年启动针对R/R MM和原发性浆细胞淋巴瘤的Ib期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1585","BK1574","BK1161","02171","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116699470","title":"异动解读 | 科济药业-B盘中大跌5.04%，前期利好兑现后股价连续回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1116699470","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116699470?lang=zh_cn&edition=full","pubTime":"2026-04-22 10:31","pubTimestamp":1776825083,"startTime":"0","endTime":"0","summary":"科济药业-B今日盘中大跌5.04%，报23.74港元/股，成交额约8073万港元。消息面上，科济药业此前因自主研发的舒瑞基奥仑赛注射液（satri-cel）研究成果在国际顶级医学期刊《柳叶刀》正式刊载，盘中一度大涨逾10%。该成果标志着公司在实体瘤CAR-T疗法领域取得重要突破。然而，利好消息兑现后，股价连续两个交易日回落，累计回吐前期涨幅。当前股价已回落至利好发布前水平附近，短期获利盘出清压力较为明显。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110240414","title":"异动解读 | 科济药业-B盘中大涨10.92%，CAR-T疗法研究成果登《柳叶刀》提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1110240414","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110240414?lang=zh_cn&edition=full","pubTime":"2026-04-20 09:40","pubTimestamp":1776649210,"startTime":"0","endTime":"0","summary":"科济药业-B今日盘中大涨10.92%，引起了市场的广泛关注。消息面上，公司自主研发的舒瑞基奥仑赛注射液（satri-cel）研究成果于近日在国际顶级医学期刊《柳叶刀》正式刊载，标志着公司在实体瘤CAR-T疗法领域取得重要突破。实体瘤CAR-T治疗长期被视为行业难点，此次研究成果获权威期刊认可，显著提升了市场对其核心管线商业化前景的预期。此外，近期诺和诺德与OpenAI达成战略合作，AI赋能创新药研发的利好情绪持续发酵，港股创新药板块整体表现活跃，亦对公司股价形成板块层面的支撑。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.carsgen.com","stockEarnings":[{"period":"1week","weight":-0.0797},{"period":"1month","weight":-0.3458},{"period":"3month","weight":-0.0285},{"period":"6month","weight":-0.0372},{"period":"1year","weight":-0.354},{"period":"ytd","weight":0.0114}],"compareEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":-0.0633},{"period":"3month","weight":-0.0294},{"period":"6month","weight":-0.0485},{"period":"1year","weight":0.0284},{"period":"ytd","weight":-0.0356}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"科济药业控股有限公司是一家主要从事探索、研发细胞疗法的投资控股公司。该公司的主营业务是从事开发嵌合抗原受体T细胞（CAR-T）细胞疗法，以满足临床需求，包括但不限于血液恶性肿瘤、实体瘤及自身免疫性疾病。该公司的主要产品包括赛恺泽（泽沃基奥仑赛注射液）、舒瑞基奥仑赛注射液、通用型CAR-T细胞产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.07858},{"month":2,"riseRate":0.6,"avgChangeRate":0.230493},{"month":3,"riseRate":0.2,"avgChangeRate":-0.058535},{"month":4,"riseRate":0.4,"avgChangeRate":-0.02351},{"month":5,"riseRate":0.6,"avgChangeRate":0.035849},{"month":6,"riseRate":0.4,"avgChangeRate":-0.007384},{"month":7,"riseRate":0.4,"avgChangeRate":-0.015336},{"month":8,"riseRate":0.6,"avgChangeRate":0.066197},{"month":9,"riseRate":0.4,"avgChangeRate":0.033481},{"month":10,"riseRate":0.6,"avgChangeRate":0.024843},{"month":11,"riseRate":0.6,"avgChangeRate":0.051023},{"month":12,"riseRate":0.4,"avgChangeRate":-0.058482}],"exchange":"SEHK","name":"科济药业-B","nameEN":"CARSGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科济药业-B(02171)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科济药业-B,02171,科济药业-B股票,科济药业-B股票老虎,科济药业-B股票老虎国际,科济药业-B行情,科济药业-B股票行情,科济药业-B股价,科济药业-B股市,科济药业-B股票价格,科济药业-B股票交易,科济药业-B股票购买,科济药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科济药业-B(02171)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}